Base de dados : MEDLINE
Pesquisa : C04.557.470.200.025.290.750 [Categoria DeCS]
Referências encontradas : 730 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 73 ir para página                         

  1 / 730 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390362
[Au] Autor:Corrias G; Horvat N; Monti S; Basturk O; Lin O; Saba L; Bodei L; Reidy DL; Mannelli L
[Ad] Endereço:Department of Radiology, Memorial Sloan Kettering Cancer Center, NY.
[Ti] Título:Malignant transformation of glucagonoma with SPECT/CT In-111 OctreoScan features: A case report.
[So] Source:Medicine (Baltimore);96(50):e9252, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Glucagonoma is an uncommon disease but it has been associated with a pattern of symptoms defined as glucagonoma syndrome. These symptoms, if promptly recognized, could help to speed up the diagnosing process. PATIENT CONCERNS: We report a case of a 68-year-old woman with a pancreatic glucagonoma. Her symptoms at the onset were typical of the glucagonoma syndrome. DIAGNOSES: After a significant weight loss, she underwent a computer tomography scan of the abdomen, which showed a hypervascular lesion of the tail of the pancreas and hypervascular lesions of the liver. An ultrasound guided biopsy was performed and pathology was consistent with glucagonoma. Her blood glucagon levels were elevated. OUTCOMES: She was treated with chemotherapy and somatostatin analogs. After 4 years, the disease had a malignant transformation, and metastases suddenly started to grow up. She stopped being responsive to treatment and eventually passed away. LESSONS: Due to its rarity, clinical diagnosis is challenging and generally it comes after a long interval since the onset of symptoms. Awareness of physicians and dermatologists of the characteristic necrolytic migratory erythema, and of the other symptoms, often leads to early diagnosis.
[Mh] Termos MeSH primário: Transformação Celular Neoplásica/patologia
Glucagonoma/diagnóstico por imagem
Glucagonoma/patologia
Neoplasias Hepáticas/diagnóstico por imagem
Neoplasias Hepáticas/patologia
Neoplasias Pancreáticas/diagnóstico por imagem
Neoplasias Pancreáticas/patologia
Tomografia Computadorizada com Tomografia Computadorizada de Emissão de Fóton Único
[Mh] Termos MeSH secundário: Idoso
Evolução Fatal
Feminino
Seres Humanos
Octreotida/análogos & derivados
Compostos Radiofarmacêuticos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Radiopharmaceuticals); 0 (indium-111-octreotide); RWM8CCW8GP (Octreotide)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009252


  2 / 730 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29069049
[Au] Autor:Gao Y; Wang C; Gao Y; Chen H; Peng B; Chen W; Ran X
[Ad] Endereço:aDiabetic Foot Center, Department of Endocrinology and Metabolism bDepartment of Pathology cDepartment of Pancreatic Surgery dDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
[Ti] Título:Glucagonoma syndrome with serous oligocystic adenoma: A rare case report.
[So] Source:Medicine (Baltimore);96(43):e8448, 2017 Oct.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Glucagonoma and pancreatic serous oligocystic adenoma (SOA) are rare neuroendocrine and exocrine tumors of the pancreas, respectively. The coexistence of glucagonoma syndrome (GS) and SOA is a rare clinical condition and has not yet been reported. Additionally, necrolytic migratory erythema (NME), a hallmark clinical sign of GS, is often misdiagnosed as other skin lesions by clinicians due to their lack of related knowledge, which delays diagnosis of GS and thus exacerbates the prognosis. PATIENT CONCERNS: A 50-year-old male patient was admitted to our department because he presented with diabetes mellitus and a recurrent ulcerated skin rash. Prior to the accurate diagnosis, the skin manifestation was considered to be diabetic dermopathy. DIAGNOSES: The patient's fasting serum glucagon level was up to 871.5 pg/mL. A biopsy of the pancreatic tumor revealed a pancreatic neuroendocrine tumor, and immunoperoxidase staining revealed glucagon-positive cells. In addition, the histological examination of the pancreatic cystic lesions showed typical features of SOA. INTERVENTIONS: The patient received a pancreaticoduodenal resection and radiofrequency ablation for the hepatic nodular lesion. OUTCOMES: One week after surgery, the glucagon concentration decreased to near normal levels. The cutaneous lesions spontaneously resolved within 4 weeks after surgery. LESSONS: Because almost all glucagonomas are malignant or have malignant potential, their early recognition and correct diagnosis are very important for a better prognosis, especially in cases with NME as the only manifestation during the development of glucagonomas. It is therefore imperative that clinicians recognize NME early to make an accurate diagnosis.
[Mh] Termos MeSH primário: Cistadenoma Seroso/etiologia
Complicações do Diabetes/complicações
Glucagonoma/etiologia
Eritema Migratório Necrolítico/etiologia
Neoplasias Pancreáticas/etiologia
[Mh] Termos MeSH secundário: Diabetes Mellitus/patologia
Exantema/etiologia
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171123
[Lr] Data última revisão:
171123
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171026
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008448


  3 / 730 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28566601
[Au] Autor:Murakami T; Usui T; Nakamoto Y; Nakajima A; Mochida Y; Saito S; Shibayama T; Yamazaki N; Hatoko T; Kato T; Yonemitsu S; Muro S; Oki S
[Ad] Endereço:Department of Diabetes and Endocrinology, Osaka Red Cross Hospital, Japan.
[Ti] Título:Challenging Differential Diagnosis of Hypergastremia and Hyperglucagonemia with Chronic Renal Failure: Report of a Case with Multiple Endocrine Neoplasia Type 1.
[So] Source:Intern Med;56(11):1375-1381, 2017.
[Is] ISSN:1349-7235
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:A 53-year-old woman developed end-stage renal failure during a 15-year clinical course of primary hyperparathyroidism and was referred to our hospital for evaluation of suspected multiple endocrine neoplasia type 1 (MEN1). Genetic testing revealed a novel deletion mutation at codon 467 in exon 10 of the MEN1 gene. Systemic and selective arterial calcium injection (SACI) testing revealed hyperglucagonemia and hypergastrinemia with positive gastrin responses. A pathological examination revealed glucagonoma and a lymph node gastrinoma. The findings in this case indicate the importance of early diagnosis of MEN1 and demonstrate the utility of systemic and SACI testing in renal failure cases.
[Mh] Termos MeSH primário: Neoplasia Endócrina Múltipla Tipo 1/diagnóstico
Neoplasia Endócrina Múltipla Tipo 1/fisiopatologia
[Mh] Termos MeSH secundário: Diagnóstico Diferencial
Feminino
Gastrinoma/diagnóstico
Glucagonoma/diagnóstico
Seres Humanos
Falência Renal Crônica/diagnóstico
Linfonodos/patologia
Meia-Idade
Neoplasia Endócrina Múltipla Tipo 1/genética
Neoplasias Pancreáticas/diagnóstico
Proteínas Proto-Oncogênicas
Insuficiência Renal Crônica/genética
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (MEN1 protein, human); 0 (Proto-Oncogene Proteins)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170602
[St] Status:MEDLINE
[do] DOI:10.2169/internalmedicine.56.7230


  4 / 730 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28273025
[Au] Autor:Mountjoy L; Kollmorgen D
[Ad] Endereço:Iowa Methodist Medical Center, Des Moines, IA lukemountjoy@gmail.com.
[Ti] Título:Glucagonoma-Associated Rash.
[So] Source:N Engl J Med;376(10):e18, 2017 Mar 09.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Exantema/patologia
Glucagonoma/complicações
Neoplasias Pancreáticas/complicações
[Mh] Termos MeSH secundário: Idoso
Exantema/etiologia
Glucagonoma/patologia
Seres Humanos
Masculino
Neoplasias Pancreáticas/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170420
[Lr] Data última revisão:
170420
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170309
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMicm1603135


  5 / 730 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28188614
[Au] Autor:Bonnavion R; Teinturier R; Gherardi S; Leteurtre E; Yu R; Cordier-Bussat M; Du R; Pattou F; Vantyghem MC; Bertolino P; Lu J; Zhang CX
[Ad] Endereço:INSERM U1052, Lyon, France.
[Ti] Título:Foxa2, a novel protein partner of the tumour suppressor menin, is deregulated in mouse and human MEN1 glucagonomas.
[So] Source:J Pathol;242(1):90-101, 2017 May.
[Is] ISSN:1096-9896
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Foxa2, known as one of the pioneer factors, plays a crucial role in islet development and endocrine functions. Its expression and biological functions are regulated by various factors, including, in particular, insulin and glucagon. However, its expression and biological role in adult pancreatic α-cells remain elusive. In the current study, we showed that Foxa2 was overexpressed in islets from α-cell-specific Men1 mutant mice, at both the transcriptional level and the protein level. More importantly, immunostaining analyses showed its prominent nuclear accumulation, specifically in α-cells, at a very early stage after Men1 disruption. Similar nuclear FOXA2 expression was also detected in a substantial proportion (12/19) of human multiple endocrine neoplasia type 1 (MEN1) glucagonomas. Interestingly, our data revealed an interaction between Foxa2 and menin encoded by the Men1 gene. Furthermore, using several approaches, we demonstrated the relevance of this interaction in the regulation of two tested Foxa2 target genes, including the autoregulation of the Foxa2 promoter by Foxa2 itself. The current study establishes menin, a novel protein partner of Foxa2, as a regulator of Foxa2, the biological functions of which extend beyond the pancreatic endocrine cells. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
[Mh] Termos MeSH primário: Glucagonoma/metabolismo
Fator 3-beta Nuclear de Hepatócito/biossíntese
Neoplasia Endócrina Múltipla Tipo 1/metabolismo
Neoplasias Pancreáticas/metabolismo
[Mh] Termos MeSH secundário: Animais
Regulação Neoplásica da Expressão Gênica
Glucagonoma/genética
Fator 3-beta Nuclear de Hepatócito/genética
Seres Humanos
Camundongos Transgênicos
Neoplasia Endócrina Múltipla Tipo 1/genética
Proteínas de Neoplasias/genética
Proteínas de Neoplasias/metabolismo
Neoplasias Pancreáticas/genética
Regiões Promotoras Genéticas/genética
Proteínas Proto-Oncogênicas/genética
Proteínas Proto-Oncogênicas/metabolismo
Transfecção
Células Tumorais Cultivadas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (FOXA2 protein, human); 0 (Foxa2 protein, mouse); 0 (MEN1 protein, human); 0 (Men1 protein, mouse); 0 (Neoplasm Proteins); 0 (Proto-Oncogene Proteins); 135845-92-0 (Hepatocyte Nuclear Factor 3-beta)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170509
[Lr] Data última revisão:
170509
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170212
[St] Status:MEDLINE
[do] DOI:10.1002/path.4885


  6 / 730 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28108603
[Au] Autor:Holst JJ; Wewer Albrechtsen NJ; Pedersen J; Knop FK
[Ad] Endereço:Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark jjholst@sund.ku.dk.
[Ti] Título:Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver-α-Cell Axis.
[So] Source:Diabetes;66(2):235-240, 2017 Feb.
[Is] ISSN:1939-327X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Glucagon is usually viewed as an important counterregulatory hormone in glucose metabolism, with actions opposing those of insulin. Evidence exists that shows glucagon is important for minute-to-minute regulation of postprandial hepatic glucose production, although conditions of glucagon excess or deficiency do not cause changes compatible with this view. In patients with glucagon-producing tumors (glucagonomas), the most conspicuous signs are skin lesions (necrolytic migratory erythema), while in subjects with inactivating mutations of the glucagon receptor, pancreatic swelling may be the first sign; neither condition is necessarily associated with disturbed glucose metabolism. In glucagonoma patients, amino acid turnover and ureagenesis are greatly accelerated, and low plasma amino acid levels are probably at least partly responsible for the necrolytic migratory erythema, which resolves after amino acid administration. In patients with receptor mutations (and in knockout mice), pancreatic swelling is due to α-cell hyperplasia with gross hypersecretion of glucagon, which according to recent groundbreaking research may result from elevated amino acid levels. Additionally, solid evidence indicates that ureagenesis, and thereby amino acid levels, is critically controlled by glucagon. Together, this constitutes a complete endocrine system; feedback regulation involving amino acids regulates α-cell function and secretion, while glucagon, in turn, regulates amino acid turnover.
[Mh] Termos MeSH primário: Aminoácidos/metabolismo
Células Secretoras de Glucagon/metabolismo
Glucagon/metabolismo
Glucose/metabolismo
Fígado/metabolismo
[Mh] Termos MeSH secundário: Animais
Retroalimentação
Glucagonoma/metabolismo
Seres Humanos
Camundongos
Mutação
Neoplasias Pancreáticas/metabolismo
Receptores de Glucagon/genética
Ureia/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amino Acids); 0 (Receptors, Glucagon); 8W8T17847W (Urea); 9007-92-5 (Glucagon); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170605
[Lr] Data última revisão:
170605
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170122
[St] Status:MEDLINE
[do] DOI:10.2337/db16-0994


  7 / 730 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27631840
[Au] Autor:Sathyakumar S; Cherian KE; Jebasingh F; Hepzhibah J; Kapoor N; Paul TV
[Ad] Endereço:From the 1Department of Endocrinology, Diabetes & Metabolism, Christian Medical College, Vellore, India.
[Ti] Título:Visual Vignette.
[So] Source:Endocr Pract;23(1):116, 2017 Jan.
[Is] ISSN:1530-891X
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Glucagonoma/diagnóstico por imagem
Eritema Migratório Necrolítico/diagnóstico
Neoplasias Pancreáticas/diagnóstico por imagem
[Mh] Termos MeSH secundário: Anemia/etiologia
Queilite/etiologia
Diabetes Mellitus/etiologia
Feminino
Radioisótopos de Gálio
Glossite/etiologia
Glucagonoma/complicações
Seres Humanos
Meia-Idade
Eritema Migratório Necrolítico/etiologia
Compostos Organometálicos
Neoplasias Pancreáticas/complicações
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons
Tomografia Computadorizada por Raios X
Perda de Peso
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Gallium Radioisotopes); 0 (Organometallic Compounds); 9L17Y0H71P (dotatate gallium ga-68)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170622
[Lr] Data última revisão:
170622
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160916
[St] Status:MEDLINE
[do] DOI:10.4158/EP161307.VV


  8 / 730 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27422791
[Au] Autor:Sansoni V; Vernillo G; Perego S; Barbuti A; Merati G; Schena F; La Torre A; Banfi G; Lombardi G
[Ad] Endereço:Laboratory of Experimental Biochemistry & Molecular Biology, IRCCS Istituto Ortopedico Galeazzi, Milano, Italy.
[Ti] Título:Bone turnover response is linked to both acute and established metabolic changes in ultra-marathon runners.
[So] Source:Endocrine;56(1):196-204, 2017 Apr.
[Is] ISSN:1559-0100
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bone and energy metabolisms regulation depends on a two-way street aimed at regulating energy utilization. Mountain ultra-marathons are highly demanding aerobic performances that deeply affect the whole body homeostasis. In this study we aimed to investigate and characterize the metabolic profile (in terms of hormones involved in energy metabolism), the inflammatory adipokines, and the bone turnover; in particular the osteocalcin-mediated response has been compared in experienced mountain ultra-marathons runners versus control subjects. Serum concentrations of specific markers of bone turnover (pro-collagen type I N-terminal propeptide, carboxylated/undercarboxylated osteocalcin), measured by enzyme-linked immunosorbent assay, and metabolic hormones (C-peptide, insulin, glucagon, glucagon-like peptide, gastric-inhibitory peptide, ghrelin, leptin, resistin, and visfatin), measured by fluorescent-based multiplex assay, were compared before and after a 65 km mountain ultra-marathons in 17 trained runners and 12 age-matched controls characterized by a low physical activity profile. After the mountain ultra-marathons, runners experienced a reduction in pro-collagen type I N-terminal propeptide, though it remained higher than in controls; while carboxylated osteocalcin remained unchanged. Among the metabolic hormones, only glucagon and leptin were different between runners and controls at rest. C-peptide and leptin decreased after the mountain ultra-marathons in runners; while glucagon, glucagon-like peptide 1, resistin, and visfatin were all increased. Uncarboxylated osteocalcin (and uncarboxylated/carboxylated osteocalcin ratio) was decreased and this highly correlated with insulin and C-peptide levels. In conditions of high energy expenditure, homeostasis is maintained at expenses of bone metabolism. Changes in the uncarboxylated osteocalcin clearly mark the global energy needs of the body.
[Mh] Termos MeSH primário: Remodelação Óssea/fisiologia
Osteocalcina/sangue
Fosfopeptídeos/sangue
Resistência Física/fisiologia
Pró-Colágeno/sangue
Corrida/fisiologia
[Mh] Termos MeSH secundário: Adipocinas/sangue
Adulto
Biomarcadores/sangue
Glicemia
Peptídeo C/sangue
Metabolismo Energético/fisiologia
Polipeptídeo Inibidor Gástrico/sangue
Peptídeo 1 Semelhante ao Glucagon/sangue
Glucagonoma/sangue
Homeostase/fisiologia
Seres Humanos
Insulina/sangue
Masculino
Meia-Idade
Nicotinamida Fosforribosiltransferase/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adipokines); 0 (Biomarkers); 0 (Blood Glucose); 0 (C-Peptide); 0 (Insulin); 0 (N-propeptide type I collagen); 0 (Phosphopeptides); 0 (Procollagen); 104982-03-8 (Osteocalcin); 59392-49-3 (Gastric Inhibitory Polypeptide); 89750-14-1 (Glucagon-Like Peptide 1); EC 2.4.2.12 (Nicotinamide Phosphoribosyltransferase)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160717
[St] Status:MEDLINE
[do] DOI:10.1007/s12020-016-1012-8


  9 / 730 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27611762
[Au] Autor:Wewer Albrechtsen NJ; Kuhre RE; Pedersen J; Knop FK; Holst JJ
[Ad] Endereço:Department of Biomedical Sciences, Faculty of Health & Medical Sciences, University of Copenhagen, Denmark.
[Ti] Título:The biology of glucagon and the consequences of hyperglucagonemia.
[So] Source:Biomark Med;10(11):1141-1151, 2016 Nov.
[Is] ISSN:1752-0371
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The proglucagon-derived peptide hormone, glucagon, comprises 29 amino acids. Its secretion from the pancreatic α cells is regulated by several factors. Glucagon increases blood glucose levels through gluconeogenesis and glycogenolysis. Elevated plasma concentrations of glucagon, hyperglucagonemia, may contribute to diabetes. However, hyperglucagonemia is also observed in other clinical conditions than diabetes, including nonalcoholic fatty liver disease, glucagon-producing tumors and after gastric bypass surgery. Here, we review the current literature on hyperglucagonemia in disease with a particular focus on diabetes, and finally speculate that the primary physiological importance of glucagon may not reside in glucose homeostasis but in regulation of amino acid metabolism exerted via a hitherto unrecognized hepato-pancreatic feedback loop.
[Mh] Termos MeSH primário: Glucagon/metabolismo
Glucagonoma/patologia
[Mh] Termos MeSH secundário: Diabetes Mellitus/metabolismo
Diabetes Mellitus/patologia
Glucagon/sangue
Glucagon/química
Peptídeo 1 Semelhante ao Glucagon/metabolismo
Glucagonoma/diagnóstico
Glucagonoma/metabolismo
Seres Humanos
Fígado/metabolismo
Neoplasias/metabolismo
Neoplasias/patologia
Hepatopatia Gordurosa não Alcoólica/metabolismo
Hepatopatia Gordurosa não Alcoólica/patologia
Oxintomodulina/metabolismo
Pâncreas/metabolismo
Receptores de Glucagon/deficiência
Receptores de Glucagon/genética
Receptores de Glucagon/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Oxyntomodulin); 0 (Receptors, Glucagon); 89750-14-1 (Glucagon-Like Peptide 1); 9007-92-5 (Glucagon)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171025
[Lr] Data última revisão:
171025
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160910
[St] Status:MEDLINE


  10 / 730 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27422767
[Au] Autor:John AM; Schwartz RA
[Ad] Endereço:Dermatology and Pathology, Rutgers-New Jersey Medical School, Newark, NJ, USA.
[Ti] Título:Glucagonoma syndrome: a review and update on treatment.
[So] Source:J Eur Acad Dermatol Venereol;30(12):2016-2022, 2016 Dec.
[Is] ISSN:1468-3083
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Glucagonoma syndrome is defined by the presence of an alpha-cell secreting tumour of the pancreas, elevated levels of glucagon, and a characteristic rash called necrolytic migratory erythema (NME). NME is usually a specific and often initial finding of glucagonoma syndrome, but it may occur in other settings unassociated with an alpha-cell pancreatic tumour (pseudoglucagonoma syndrome). Glucagonoma syndrome must be distinguished from pseudoglucagonoma syndrome. Prompt recognition of NME and subsequent workup for a glucagonoma can allow for an earlier diagnosis and enhance the chances of a favourable outcome. In particular, metastases occur late, so early recognition of glucagonoma syndrome before liver metastases can be life-saving. Surgical resection is the definitive treatment for glucagonoma syndrome, although chemotherapeutic agents, somatostatin analogues and radionuclide therapy are also employed. Herein, we offer an approach to workup after identifying NME and an update on its current treatment modalities.
[Mh] Termos MeSH primário: Glucagonoma/terapia
[Mh] Termos MeSH secundário: Glucagonoma/diagnóstico
Glucagonoma/patologia
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170421
[Lr] Data última revisão:
170421
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160717
[St] Status:MEDLINE
[do] DOI:10.1111/jdv.13752



página 1 de 73 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde